GENEVA (AP) — Swiss pharmaceuticals company Novartis says net income jumped 12 percent in the first quarter, pointing to explosive growth in its heart-failure drug Entresto as its rollout continues, and powerful double-digit percentage growth for psoriasis drug Cosentyx.
The Basel-based powerhouse, one of the world’s largest drug companies, said Thursday that first-quarter net profit under new CEO Vas Narasimhan rose to $2.03 billion when accounting for currency changes, up from $1.67 billion a year earlier.
Net sales rose 4 percent to $12.69 billion.
Sales of Cosentyx jumped 35 percent to $580 million, and Entresto sales soared 126 percent to $200 million.
Most Read Stories
- The five priciest Seattle-area homes last year sold for a combined $113M. Four went to mystery buyers. VIEW
- Special sunglasses, license-plate dresses: How to be anonymous in the age of surveillance WATCH
- Snohomish County elementary school teacher found dead from hypothermia
- New software flaw could further delay Boeing’s 737 MAX
- At gun-rights rally, Washington state Rep. Matt Shea gives fiery defense, talks of nation's 'real enemies' VIEW
Generics and biosimilars unit Sandoz saw U.S. sales drop 18 percent amid competitive pressures.
Novartis experienced double-digit percentage growth in emerging markets, largely due to an 18-percent increase in sales in China.